MetaCap

Psyence Biomedical (PBM) vs Shuttle Pharmaceuticals (SHPH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Shuttle Pharmaceuticals (SHPH) has outperformed Psyence Biomedical (PBM) over the past year, losing 78.2% versus a loss of 94.9%. Shuttle Pharmaceuticals is the larger company by market cap ($16.6 million vs $15.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PBM-94.90%SHPH-78.19%
+64%-20%-104%
Nov 21, 20251 yearNov 20, 2026
PBM-100.00%SHPH-99.99%
+173%+30%-113%
Aug 29, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PBM versus SHPH key metrics
MetricPBMSHPH
Share price$2.97$3.49
Market cap$15.80M$16.63M
1-day change+3.85%-10.51%
YTD return-89.90%-80.61%
1-year return-94.90%-78.19%
EPS (TTM)$-12.56$-16.87
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$1.01M$-11.72M
52-week high$73.44$44.40
52-week low$1.92$2.58
Distance from 52-week high-95.96%-92.14%
Average volume61.93K41.80K
Shares outstanding5.32M4.76M
Employees122
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SHPH has outperformed PBM by 16.7 percentage points over the past year.

About Psyence Biomedical

PBM stock →

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About Shuttle Pharmaceuticals

SHPH stock →

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

PBM vs SHPH FAQ

Which is bigger, Psyence Biomedical or Shuttle Pharmaceuticals?

Shuttle Pharmaceuticals (SHPH) is larger, with a market capitalization of $16.63M compared with $15.80M for Psyence Biomedical (PBM).

Which stock has performed better over the past year, PBM or SHPH?

SHPH returned -78.19% over the past 12 months, compared with -94.90% for PBM (price return, excluding dividends). Past performance does not predict future results.

Are Psyence Biomedical and Shuttle Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons